がん幹細胞の市場シェア、規模、動向分析レポート:作用機序別(幹細胞ベースのがん治療、標的CSC)、がん形態別(乳がん、膀胱がん)、地域別、セグメント別予測、2023年~2030年Cancer Stem Cells Market Share, Size & Trends Analysis Report By Mode Of Action (Stem Cell based Cancer Therapy, Targeted CSCs), By Cancer Forms (Breast Cancer, Bladder Cancer), By Region, And Segment Forecasts, 2023 - 2030 がん幹細胞市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の癌幹細胞市場規模は2030年までに31億米ドルに達し、予測期間中の年平均成長率は12.09%で拡大すると予測されている。幹細... もっと見る
本レポートは受注生産のため、ご納品のお時間をいただく場合がございます。
サマリーがん幹細胞市場の成長と動向Grand View Research, Inc.の最新レポートによると、世界の癌幹細胞市場規模は2030年までに31億米ドルに達し、予測期間中の年平均成長率は12.09%で拡大すると予測されている。幹細胞を用いたがん治療は規制や倫理的な課題に直面しているが、市場は世界的に拡大している。幹細胞に対する認識が高まるにつれ、幹細胞を用いた効果的かつ新規の治療法開発のための研究開発も着実に成長している。 さらに、がん幹細胞(CSC)に関する研究発表の数も増加の一途をたどっている。これらの研究は、医療関係者がCSCsの生物学とそのシグナル伝達経路に関する洞察を得るのに役立っている。このことは、同市場に大きな成長の可能性をもたらすと期待されている。 さらに、実験的アプローチ、特にin vitroアッセイシステムの改善により、科学者は腫瘍内の異なる細胞タイプとその微小環境との関係を確立できるようになった。このことは、腫瘍の成長を抑制し、臨床転帰を改善するために、CSCsとそれに関連する重要な経路に対する幅広い治療ポートフォリオの開発につながっている。 癌幹細胞市場レポートハイライト - 栄養補助食品は、2022年の売上高シェアで60%を占め、市場を支配している。これは、栄養補助食品における消費者の嗜好が、化学ベースの成分からオーガニックやハーブの成分へと変化しているためである。 - 電子商取引の普及とオンラインで製品を提供するプレイヤーの増加により、オンラインストアは予測期間中最も急成長する流通チャネルになると予想される。 - 北米がカンナビジオール消費者向け健康製品の癌幹細胞市場を支配し、2022年の売上高シェアは約70%。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Mode of action 1.1.2. Cancer forms 1.1.3. Regional scope 1.1.4. Estimates and forecast timeline 1.2. Research Methodology 1.3. Information Procurement 1.3.1. Purchased database 1.3.2. GVR’s internal database 1.3.3. Secondary sources 1.3.4. Primary research 1.3.5. Details of primary research 1.4. Information or Data Analysis 1.5. Market Formulation & Validation 1.6. Model Details 1.7. List of Secondary Sources 1.8. List of Primary Sources 1.9. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Mode of action 2.2.2. Cancer forms 2.2.3. Regional outlook 2.3. Competitive Insights Chapter 3. Cancer Stem Cells Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Industry Value Chain Analysis 3.3.1. Reimbursement framework 3.4. Market Dynamics 3.4.1. Market Driver Analysis 3.4.2. Market Restraint Analysis 3.5. Cancer Stem Cells Market Analysis Tools 3.5.1. Industry Analysis - Porter’s 3.5.1.1. Supplier power 3.5.1.2. Buyer power 3.5.1.3. Substitution threat 3.5.1.4. Threat of new entrant 3.5.1.5. Competitive rivalry 3.5.2. PESTEL Analysis 3.5.2.1. Political landscape 3.5.2.2. Technological landscape 3.5.2.3. Economic Landscape Chapter 4. Cancer Stem Cells: Mode of Action Estimates & Trend Analysis 4.1. Cancer Stem Cells Market: Key Takeaways 4.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030 4.3. Targeted Cancerous Stem Cells (CSCs) 4.3.1. Targeted cancerous stem cells market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1. By anti-cancer stem cell therapeutics 4.3.1.1.1. By anti-cancer stem cell therapeutics market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1. Pathway inhibitors 4.3.1.1.1.1.1. Pathway inhibitors market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.1. WNT signaling pathway 4.3.1.1.1.1.1.1.1. WNT signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.2. Hedgehog signaling pathway 4.3.1.1.1.1.1.2.1. Hedgehog signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.3. Notch signaling pathway 4.3.1.1.1.1.1.3.1. Notch signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.4. Others 4.3.1.1.1.1.1.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.2. Surface marker-based 4.3.1.1.1.2.1. Surface marker-based market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.3. Immuno-evasion & targeting tumor microenvironment 4.3.1.1.1.3.1. Immuno-evasion & targeting tumor microenvironment market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.4. Nanoparticle-based therapies 4.3.1.1.1.4.1. Nanoparticle-based therapies market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.5. Others 4.3.1.1.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2. By-products 4.3.1.2.1. By products market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.1. Cell culturing 4.3.1.2.1.1.1. Cell culturing market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.2. Cell Separation 4.3.1.2.1.2.1. Cell separation market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.3. Cell Analysis 4.3.1.2.1.3.1. Cell analysis market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.4. Molecular analysis 4.3.1.2.1.4.1. Molecular analysis market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.5. Others 4.3.1.2.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million) 4.4. Stem Cell-based Cancer Therapy 4.4.1. Stem cell-based cancer therapy market estimates and forecasts, 2018 to 2030 (USD Million) 4.4.1.1. Autologous stem cell transplant 4.4.1.1.1. Autologous stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million) 4.4.1.2. Allogeneic stem cell transplant 4.4.1.2.1. Allogeneic stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 5. Cancer Stem Cells: Cancer Forms Estimates & Trend Analysis 5.1. Cancer Stem Cells Market: Key Takeaways 5.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030 5.3. Breast Cancer 5.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.4. Blood Cancer 5.4.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.5. Lung Cancer 5.5.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.6. Brain Cancer 5.6.1. Brain cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.7. Colorectal Cancer 5.7.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.8. Pancreatic Cancer 5.8.1. Pancreatic cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.9. Bladder Cancer 5.9.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.10. Liver Cancer 5.10.1. Liver cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.11. Other Cancer 5.11.1. Other cancer market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 6. Cancer Stem Cells Market: Regional Estimates & Trend Analysis 6.1. Regional Outlook 6.2. Cancer Stem Cells Market by Region: Key Marketplace Takeaway 6.3. North America 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.3.2. U.S. 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.3.3. Canada 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4. Europe 6.4.1. UK 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.2. Germany 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.3. France 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.4. Italy 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.5. Spain 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.6. Sweden 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.7. Norway 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.8. Denmark 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5. Asia Pacific 6.5.1. Japan 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.2. China 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.3. India 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.4. Australia 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.5. Thailand 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.6. South Korea 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.6. Latin America 6.6.1. Brazil 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.6.2. Mexico 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.6.3. Argentina 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7. MEA 6.7.1. Saudi Arabia 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7.2. South Africa 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7.3. UAE 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7.4. Kuwait 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) Chapter 7. Competitive Landscape 7.1. Recent Developments & Impact Analysis, By Key Market Participants 7.2. Market Participant Categorization 7.2.1. Thermo Fisher Scientific, Inc. 7.2.1.1. Company overview 7.2.1.2. Financial performance 7.2.1.3. Product Benchmarking 7.2.1.4. Strategic initiatives 7.2.2. AbbVie, Inc. 7.2.2.1. Company overview 7.2.2.2. Financial performance 7.2.2.3. Product benchmarking 7.2.2.4. Strategic initiatives 7.2.3. Merck KGaA 7.2.3.1. Company overview 7.2.3.2. Financial performance 7.2.3.3. Product benchmarking 7.2.3.4. Strategic initiatives 7.2.4. Bionomics 7.2.4.1. Company overview 7.2.4.2. Financial performance 7.2.4.3. Product benchmarking 7.2.4.4. Strategic initiatives 7.2.5. Lonza 7.2.5.1. Company overview 7.2.5.2. Financial performance 7.2.5.3. Product benchmarking 7.2.5.4. Strategic initiatives 7.2.6. Stemline Therapeutics, Inc. 7.2.6.1. Company overview 7.2.6.2. Financial performance 7.2.6.3. Product benchmarking 7.2.6.4. Strategic initiatives 7.2.7. Miltenyi Biotec 7.2.7.1. Company overview 7.2.7.2. Financial performance 7.2.7.3. Product benchmarking 7.2.7.4. Strategic initiatives 7.2.8. PromoCell GmbH 7.2.8.1. Company overview 7.2.8.2. Financial performance 7.2.8.3. Product benchmarking 7.2.8.4. Strategic initiatives 7.2.9. MacroGenics, Inc. 7.2.9.1. Company overview 7.2.9.2. Financial performance 7.2.9.3. Product benchmarking 7.2.9.4. Strategic initiatives 7.2.10. FUJIFILM Irvine Scientific 7.2.10.1. Company overview 7.2.10.2. Financial performance 7.2.10.3. Product benchmarking 7.2.10.4. Strategic initiatives 7.2.11. STEMCELL Technologies. 7.2.11.1. Company overview 7.2.11.2. Financial performance 7.2.11.3. Product benchmarking 7.2.11.4. Strategic initiatives 7.2.12. Sino Biological, Inc. 7.2.12.1. Company overview 7.2.12.2. Financial performance 7.2.12.3. Product benchmarking 7.2.12.4. Strategic initiatives 7.2.13. Lineage Cell Therapeutics, Inc. 7.2.13.1. Company overview 7.2.13.2. Financial performance 7.2.13.3. Product benchmarking 7.2.13.4. Strategic initiatives
SummaryCancer Stem Cells Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Mode of action 1.1.2. Cancer forms 1.1.3. Regional scope 1.1.4. Estimates and forecast timeline 1.2. Research Methodology 1.3. Information Procurement 1.3.1. Purchased database 1.3.2. GVR’s internal database 1.3.3. Secondary sources 1.3.4. Primary research 1.3.5. Details of primary research 1.4. Information or Data Analysis 1.5. Market Formulation & Validation 1.6. Model Details 1.7. List of Secondary Sources 1.8. List of Primary Sources 1.9. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Mode of action 2.2.2. Cancer forms 2.2.3. Regional outlook 2.3. Competitive Insights Chapter 3. Cancer Stem Cells Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Industry Value Chain Analysis 3.3.1. Reimbursement framework 3.4. Market Dynamics 3.4.1. Market Driver Analysis 3.4.2. Market Restraint Analysis 3.5. Cancer Stem Cells Market Analysis Tools 3.5.1. Industry Analysis - Porter’s 3.5.1.1. Supplier power 3.5.1.2. Buyer power 3.5.1.3. Substitution threat 3.5.1.4. Threat of new entrant 3.5.1.5. Competitive rivalry 3.5.2. PESTEL Analysis 3.5.2.1. Political landscape 3.5.2.2. Technological landscape 3.5.2.3. Economic Landscape Chapter 4. Cancer Stem Cells: Mode of Action Estimates & Trend Analysis 4.1. Cancer Stem Cells Market: Key Takeaways 4.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030 4.3. Targeted Cancerous Stem Cells (CSCs) 4.3.1. Targeted cancerous stem cells market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1. By anti-cancer stem cell therapeutics 4.3.1.1.1. By anti-cancer stem cell therapeutics market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1. Pathway inhibitors 4.3.1.1.1.1.1. Pathway inhibitors market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.1. WNT signaling pathway 4.3.1.1.1.1.1.1.1. WNT signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.2. Hedgehog signaling pathway 4.3.1.1.1.1.1.2.1. Hedgehog signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.3. Notch signaling pathway 4.3.1.1.1.1.1.3.1. Notch signaling pathway market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.1.1.4. Others 4.3.1.1.1.1.1.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.2. Surface marker-based 4.3.1.1.1.2.1. Surface marker-based market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.3. Immuno-evasion & targeting tumor microenvironment 4.3.1.1.1.3.1. Immuno-evasion & targeting tumor microenvironment market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.4. Nanoparticle-based therapies 4.3.1.1.1.4.1. Nanoparticle-based therapies market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.1.1.5. Others 4.3.1.1.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2. By-products 4.3.1.2.1. By products market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.1. Cell culturing 4.3.1.2.1.1.1. Cell culturing market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.2. Cell Separation 4.3.1.2.1.2.1. Cell separation market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.3. Cell Analysis 4.3.1.2.1.3.1. Cell analysis market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.4. Molecular analysis 4.3.1.2.1.4.1. Molecular analysis market estimates and forecasts, 2018 to 2030 (USD Million) 4.3.1.2.1.5. Others 4.3.1.2.1.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million) 4.4. Stem Cell-based Cancer Therapy 4.4.1. Stem cell-based cancer therapy market estimates and forecasts, 2018 to 2030 (USD Million) 4.4.1.1. Autologous stem cell transplant 4.4.1.1.1. Autologous stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million) 4.4.1.2. Allogeneic stem cell transplant 4.4.1.2.1. Allogeneic stem cell transplant market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 5. Cancer Stem Cells: Cancer Forms Estimates & Trend Analysis 5.1. Cancer Stem Cells Market: Key Takeaways 5.2. Cancer Stem Cells Market: Movement & Market Share Analysis, 2022 & 2030 5.3. Breast Cancer 5.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.4. Blood Cancer 5.4.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.5. Lung Cancer 5.5.1. Lung cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.6. Brain Cancer 5.6.1. Brain cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.7. Colorectal Cancer 5.7.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.8. Pancreatic Cancer 5.8.1. Pancreatic cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.9. Bladder Cancer 5.9.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.10. Liver Cancer 5.10.1. Liver cancer market estimates and forecasts, 2018 to 2030 (USD Million) 5.11. Other Cancer 5.11.1. Other cancer market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 6. Cancer Stem Cells Market: Regional Estimates & Trend Analysis 6.1. Regional Outlook 6.2. Cancer Stem Cells Market by Region: Key Marketplace Takeaway 6.3. North America 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.3.2. U.S. 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.3.3. Canada 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4. Europe 6.4.1. UK 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.2. Germany 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.3. France 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.4. Italy 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.5. Spain 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.6. Sweden 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.7. Norway 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.4.8. Denmark 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5. Asia Pacific 6.5.1. Japan 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.2. China 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.3. India 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.4. Australia 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.5. Thailand 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.5.6. South Korea 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.6. Latin America 6.6.1. Brazil 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.6.2. Mexico 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.6.3. Argentina 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7. MEA 6.7.1. Saudi Arabia 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7.2. South Africa 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7.3. UAE 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) 6.7.4. Kuwait 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million) Chapter 7. Competitive Landscape 7.1. Recent Developments & Impact Analysis, By Key Market Participants 7.2. Market Participant Categorization 7.2.1. Thermo Fisher Scientific, Inc. 7.2.1.1. Company overview 7.2.1.2. Financial performance 7.2.1.3. Product Benchmarking 7.2.1.4. Strategic initiatives 7.2.2. AbbVie, Inc. 7.2.2.1. Company overview 7.2.2.2. Financial performance 7.2.2.3. Product benchmarking 7.2.2.4. Strategic initiatives 7.2.3. Merck KGaA 7.2.3.1. Company overview 7.2.3.2. Financial performance 7.2.3.3. Product benchmarking 7.2.3.4. Strategic initiatives 7.2.4. Bionomics 7.2.4.1. Company overview 7.2.4.2. Financial performance 7.2.4.3. Product benchmarking 7.2.4.4. Strategic initiatives 7.2.5. Lonza 7.2.5.1. Company overview 7.2.5.2. Financial performance 7.2.5.3. Product benchmarking 7.2.5.4. Strategic initiatives 7.2.6. Stemline Therapeutics, Inc. 7.2.6.1. Company overview 7.2.6.2. Financial performance 7.2.6.3. Product benchmarking 7.2.6.4. Strategic initiatives 7.2.7. Miltenyi Biotec 7.2.7.1. Company overview 7.2.7.2. Financial performance 7.2.7.3. Product benchmarking 7.2.7.4. Strategic initiatives 7.2.8. PromoCell GmbH 7.2.8.1. Company overview 7.2.8.2. Financial performance 7.2.8.3. Product benchmarking 7.2.8.4. Strategic initiatives 7.2.9. MacroGenics, Inc. 7.2.9.1. Company overview 7.2.9.2. Financial performance 7.2.9.3. Product benchmarking 7.2.9.4. Strategic initiatives 7.2.10. FUJIFILM Irvine Scientific 7.2.10.1. Company overview 7.2.10.2. Financial performance 7.2.10.3. Product benchmarking 7.2.10.4. Strategic initiatives 7.2.11. STEMCELL Technologies. 7.2.11.1. Company overview 7.2.11.2. Financial performance 7.2.11.3. Product benchmarking 7.2.11.4. Strategic initiatives 7.2.12. Sino Biological, Inc. 7.2.12.1. Company overview 7.2.12.2. Financial performance 7.2.12.3. Product benchmarking 7.2.12.4. Strategic initiatives 7.2.13. Lineage Cell Therapeutics, Inc. 7.2.13.1. Company overview 7.2.13.2. Financial performance 7.2.13.3. Product benchmarking 7.2.13.4. Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
Grand View Research社の生物分野での最新刊レポート
本レポートと同じKEY WORD(cancer)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |